Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Recruiting
Phase 3
Interventional Study
Obesity and Cardiovascular Risk
Insulin Resistance
Obesity (Body Mass Index >30 kg/m2)
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 20 – 59
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 220 (estimated)
- Sponsor
- University Of Nigeria Teaching Hospital · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.
Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects hav…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* • Obesity (defined as body mass index ≥ 30kg/m2),
* Fasting plasma glucose (\<7.0mmol/L)
* No medical treatment for weight control in the previous 12 months
* No participation in a current clinical trial
Exclusion Criteria:
* • Obesity (defined as body mass index ≥ 30…
Contacts